These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 33277167

  • 1. Visceral Aneurysm Formation and Intraabdominal Hemorrhage Associated with Immune Checkpoint Inhibitor Therapy.
    Lee AY, Lam A, Hicks RM, Isikbay M, Heller MB, Sugi MD, Behr S, Kohi MP.
    J Vasc Interv Radiol; 2021 Jan; 32(1):151-152. PubMed ID: 33277167
    [No Abstract] [Full Text] [Related]

  • 2. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC, Kosova K, Bohne AS, Schreiber S, Hauschild A.
    Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
    [No Abstract] [Full Text] [Related]

  • 3. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T, Doerler M, Scheel CH.
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract] [Full Text] [Related]

  • 4. [Not Available].
    Bos D, Reichardt B, Tecklenborg K, Wetter A.
    Rofo; 2020 May; 192(5):471-472. PubMed ID: 31918442
    [No Abstract] [Full Text] [Related]

  • 5. Vogt-Koyanagi-Harada-like syndrome induced by immune checkpoint inhibitors in a patient with melanoma.
    Yoshida S, Shiraishi K, Mito T, Sayama K.
    Clin Exp Dermatol; 2020 Oct; 45(7):908-911. PubMed ID: 32394515
    [No Abstract] [Full Text] [Related]

  • 6. Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.
    Andersson NW, Zachariae C, Simonsen AB.
    Eur J Cancer; 2021 Mar; 145():168-170. PubMed ID: 33486439
    [No Abstract] [Full Text] [Related]

  • 7. Rare, but Severe: Vasculitis and Checkpoint Inhibitors.
    Lindner AK, Gruenbacher G, Schachtner G, Thurnher M, Pichler R.
    Eur Urol Focus; 2020 May 15; 6(3):609-612. PubMed ID: 31072806
    [Abstract] [Full Text] [Related]

  • 8. Gastrointestinal: Severe gastritis with complete gastric mucosal sloughing.
    Nasser R, Fisher Y, Klein A.
    J Gastroenterol Hepatol; 2021 Oct 15; 36(10):2639. PubMed ID: 33624341
    [No Abstract] [Full Text] [Related]

  • 9. Pembrolizumab in the Treatment of Breast Cancer.
    Pivot X.
    N Engl J Med; 2022 Jul 21; 387(3):273-274. PubMed ID: 35857664
    [No Abstract] [Full Text] [Related]

  • 10. Novel Onset of Cutaneous Lupus Erythematosus Induced by Pembrolizumab.
    Pogorelov D, Strotkötter H, Bjelic-Radisic V, Wesselmann U, Hübinger J, Sabulyte S, Hofmann SC, Balakirski G.
    Acta Derm Venereol; 2024 Sep 30; 104():adv40801. PubMed ID: 39347691
    [No Abstract] [Full Text] [Related]

  • 11. Pembrolizumab-Induced Liver Injury: Beyond Immune-Mediated Hepatitis.
    Herms Q, Fuster-Anglada C, Juanola A.
    Gastroenterology; 2024 Aug 30; 167(3):443-445. PubMed ID: 38320724
    [No Abstract] [Full Text] [Related]

  • 12. Immunohistochemical Expression of PD-L1 Is Increased in Lesional Epidermal Keratinocytes in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.
    Ziemer CM, Miedema J, Smith CJ, Liu Z, Thomas NE, Googe PB.
    Am J Dermatopathol; 2021 Apr 01; 43(4):318-320. PubMed ID: 33055536
    [No Abstract] [Full Text] [Related]

  • 13. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
    Raibagkar P.
    Immunol Lett; 2020 May 01; 221():72-74. PubMed ID: 32092358
    [No Abstract] [Full Text] [Related]

  • 14. Comment on: "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis".
    Noguchi Y, Yan M.
    Int J Cancer; 2023 Jul 01; 153(1):238-239. PubMed ID: 36891933
    [No Abstract] [Full Text] [Related]

  • 15. Reply to: Comments on "Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis".
    Gu T, Lin A, Wang H, Zhang J, Luo P.
    Int J Cancer; 2023 Jul 01; 153(1):240-242. PubMed ID: 36891965
    [No Abstract] [Full Text] [Related]

  • 16. [Invasive radiology and life-threatening hemorrhage. The Danish Society of Radiology].
    Nielsen DT, Dansk Radiologisk Selskab.
    Ugeskr Laeger; 2007 Mar 19; 169(12):1129. PubMed ID: 17394840
    [No Abstract] [Full Text] [Related]

  • 17. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R, Esparragosa Vazquez I, Toledano Illan C, Idoate Gastearena MA, Gállego Pérez-Larraya J.
    Neuromuscul Disord; 2020 Jan 19; 30(1):67-69. PubMed ID: 31839404
    [Abstract] [Full Text] [Related]

  • 18. Risk of infection associated with new therapies for lymphoproliferative syndromes.
    Los-Arcos I, Aguilar-Company J, Ruiz-Camps I.
    Med Clin (Barc); 2020 Feb 14; 154(3):101-107. PubMed ID: 31771856
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
    Rao BB, Robertson S, Philpott J.
    Am J Gastroenterol; 2019 Feb 14; 114(2):196. PubMed ID: 30353060
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.